[177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with prostate cancer and biochemical but not radio-morphological local recurrence after primary therapy with curative intent: A Prospective Phase II Pilot Study

You may be able to join if

• Patients must be adults ≥ 18 years of age. • Patients with BCR primarily treated with RP and patients with BCR primarily treated with RT with a PSA doubling-time (PSADT) of ≤ 12months. • No hormonal therapy within the last 12 months and/or recovered testosterone levels. • [68Ga]Ga-PSMA-11 PET negative result for local recurrence; presence of distant metastases is allowed: (cN0, cM0/cM1). • Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1 • Patients must have adequate bone marrow reserve: WBC ≥1.5 x 109 /L, Platelets ≥100 x 109 /L and Haemoglobin ≥9 g/dL. • Patients must have adequate renal function with eGFR ≥ 50mL/min/1.73m2 using the Modification of Diet Renal Disease (MDRD) equation and an Albumin level of ≥2.5 g/dL. • Patients must be able to sign Informed Consent Form.